SAN DIEGO--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented positive data from a phase II study of darinaparsin, the Company’s novel organic arsenic compound, in advanced hematological malignancies at the American Association for Cancer Research (AACR) Annual Meeting, April 12-16, 2008 in San Diego, CA.